Nithin Kamath questions India's slow uptake of affordable GLP-1 weight-loss drugs despite rising obesity, citing challenges like long-term adherence and physician conservatism, prompting a cautionary response from Kiran Mazumdar-Shaw emphasizing diet and exercise for non-diabetic, non-obese individuals.
Despite rising obesity and affordable generic GLP-1 drugs, India lags in adoption. Zerodha co-founder Nithin Kamath attributes this to patient retention issues with weekly injections and conservative doctor prescribing habits. Oral alternatives may boost uptake, suggesting convenience, not price, will drive future acceptance.
UPS is investing $48 million in 27 temperature-controlled facilities globally to meet the rising demand for GLP-1 weight-loss drugs and other sensitive medications, ensuring they remain within required temperature ranges for patient use.
The Food and Drug Administration (FDA) is considering stricter border controls for GLP-1 weight loss drugs due to illegal imports from China and online platforms. The agency is also proposing amendments to the Pharmaceutical Affairs Act to hold online platforms accountable for hosting illegal drug sales.
Demand for weight-loss drugs, cosmetic procedures, and wellness treatments is driving out-of-pocket healthcare spending in India. Most of these interventions, like Botox and anti-obesity drugs, are not covered by standard health insurance unless medically necessary. Experts advise reviewing policy exclusions and avoiding EMIs for elective treatments.
Demand for weight-loss drugs, cosmetic procedures, and wellness treatments is driving out-of-pocket healthcare expenses in India. Most of these, like Botox and anti-obesity drugs, are not covered by standard health insurance unless medically necessary, experts advise understanding policy exclusions and avoiding EMIs for elective treatments.
GLP-1 weight-loss drug users in Great Britain are saving an average of £418 annually on groceries, with household use nearly tripling in two years to 1.9 million adults. The drugs are impacting food consumption and forcing retailers to adapt.
Canada has become the first G7 nation to approve generic semaglutide injections, making GLP-1 drugs more accessible and affordable. This move by Novo Nordisk follows similar approvals in India and may pressure US prices, though generics are not expected there until 2032.
Canada has become the first G7 nation to approve generic semaglutide injections, making GLP-1 drugs more accessible and affordable. This move by Novo Nordisk follows similar approvals in India and has already led to price reductions for brand-name medications.
Research indicates that using weight-loss drugs like Mounjaro, Wegovy, and Ozempic for at least three years could significantly reduce the need for knee replacement surgeries, potentially preventing thousands of procedures annually in the US and UK.
New studies presented at a major oncology conference suggest GLP-1 weight-loss drugs could reduce cancer risk by 30%. Research indicates they may lower the likelihood of developing breast cancer, decrease mortality risk in breast cancer patients, and reduce the spread of various cancers.
CVS Health will restore coverage of Eli Lilly's weight loss injection Zepbound on Oct. 1 and add coverage of its new obesity pill Foundayo on June 1, making both GLP-1 medications co-preferred options on its standard commercial formulary, affecting 25-30 million Americans and boosting Lilly's market position against Novo Nordisk.
Experts suggest the rise of weight-loss drugs like Wegovy could influence future art, potentially popularizing a "GLP-1 face" characterized by rapid fat loss, similar to past aesthetic trends. This shift contrasts with historical art that often celebrated fuller figures.
A new wave of female pop stars, including Slayyyter, Kesha, and Tove Lo, are embracing a "trash-pop" aesthetic characterized by hedonistic lyrics, anarchic sexuality, and a "white trash" sensibility. This trend, influenced by early 00s electroclash and reality TV culture, represents a rejection of feminine respectability and a cathartic expression of anger and frustration.
A Peking Union Medical College Hospital physician advises caution with rapid weight loss methods, including "slimming injections" and diabetes medications. These are prescription drugs with specific indications and potential side effects, requiring specialist evaluation and not for self-purchase or arbitrary use. The expert specifically warns against their use in individuals under 18 due to potential impacts on growth and development.
India has become one of the first countries to introduce cheaper, generic brands of weight loss drugs like Ozempic and Wegovy, but health professionals warn a lack of regulation and oversight is causing problems.
India has become one of the first countries to introduce cheaper, generic brands of weight loss drugs like Ozempic and Wegovy, but health professionals warn a lack of regulation and oversight is causing problems.
Millions of people with Medicare will soon be eligible to get discounted GLP-1 drugs for weight loss. Here's how it will work.
Deloitte research reveals pharmaceutical R&D returns for top 20 companies reached 7% in 2025, the highest in years, driven almost entirely by GLP-1 weight loss and diabetes drugs. However, excluding these assets, returns plummet to just 2.9%. For the first time in 16 years, obesity treatments have surpassed oncology as the largest contributor to late-stage pipeline value, raising concerns about concentrated risk and a potential bubble effect.
The rising popularity of GLP-1 weight-loss drugs is driving a surge in demand for hair-care products as users report temporary hair loss. Beauty companies are now innovating and marketing specific treatments to address this growing side effect.
Research shows 12 million people lost coverage for Zepbound and 12 million for Wegovy from 2025 to 2026, with 88% of those who still have coverage facing restrictions. Patients like Meghan Lena, a Massachusetts teacher, describe losing coverage twice within months and being forced to pay $300 monthly for compounded alternatives or face treatment interruption.
Hong Kong authorities have arrested five men across two operations at registered pharmacies in Sha Tin and Jordan, seizing over 400 clonazepam tablets, 2,700 zolpidem tablets, and six boxes of unregistered slimming injections. The Department of Health announced increased enforcement against illegal sales of anti-obesity medicines classified as Part 1 poisons, citing growing demand driven by nearly half of residents being overweight or obese.
